This study explores whether clear aligners used in orthodontic treatment release very small plastic particles, known as microplastics, into the mouth. While aligners are made from safe medical-grade plastics, everyday use such as chewing, temperature changes, and saliva exposure may cause the material to gradually wear down. We will collect saliva samples from patients before starting aligner treatment and after several months of use to see if these particles can be detected. Advanced laboratory techniques will be used to identify and analyze any plastic particles present.

Our preliminary findings suggest that small plastic-related compounds may already be present in patients wearing aligners, but this study aims to confirm and better understand this in real clinical conditions. The goal is to determine how much exposure may occur and what types of materials are involved. This information will help improve the safety of orthodontic materials and guide future recommendations for both patients and providers.

This study is for patients that have been diagnosed with relapsed and refractory multiple myeloma (RRMM). This study is testing and investigational drug called KTX-1001. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). The primary purpose of this study is to test the safety and tolerability of KTX-1001 and to find out how it is processed by the body. The drug is given to participants by mouth. Participants in this study can expect to be in this study until disease progression, unacceptable toxicity, or withdrawal from the study. The total duration of the study may be approximately 4 years.

This study aims to improve the early identification of depression and substance use concerns during pregnancy and after childbirth by developing an artificial intelligence (AI) tool that uses information already collected in electronic health records. The goal is to help healthcare providers identify individuals who may be at risk for mental health or substance use problems earlier, allowing for timely support and treatment. Researchers will also work closely with patients, healthcare providers, and community partners to ensure the AI tool is trustworthy, easy to use, fair, and able to fit into routine healthcare settings.
The study includes two components. First, researchers will use existing electronic health record data from pregnant patients to develop and test an AI model that can predict the likelihood of depression or substance use concerns. Second, pregnant or postpartum individuals and obstetric healthcare providers will participate in a one-time virtual interview/focus group to share their perspectives on the use of AI in maternal healthcare. Feedback from these interviews/focus groups will help refine the AI tool and support its future implementation in clinical care.

This research study explores the experiences of adults with spinal cord injury (SCI) when managing menstrual hygiene. Recommendations for occupational therapy (OT) interventions to support participation are also included. Information will be gathered from each participant through a survey and a virtual interview. This study aims to answer the following questions: How do adults living with SCI manage menstrual hygiene? What challenges do they face? What role can OT play in supporting them?

The purpose of this research is to evaluate the safety and effectiveness of the EchoMark/EchoSure System for AVF (arteriovenous fistula) for assessing AV fistula maturation when used under a protocol of biweekly use as compared to the standard of care follow-up. Target subject population are subjects presenting with Stage 5 Chronic Kidney Disease (CKD5) or End Stage Renal Disease (ESRD) undergoing upper arm autologous arteriovenous fistula creation for hemodialysis access who are on dialysis or will imminently require dialysis (GFR <10).

This is a prospective, multicenter, observational study designed to evaluate the clinical utility and prognostic relevance of serial TRAC and T-ID monitoring in kidney transplant recipients under routine clinical care.

The study compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk. Participants can expect to remain in the study for 10 years.

This study aims to evaluate real-world effectiveness of pacritinib through a site-based retrospective chart review of medical records of adult patients with myelofibrosis treated with pacritinib in routine clinical settings with platelet count ≥50 x 10^9/L at the time of treatment initiation. Treatment effectiveness will be based on spleen size and symptom burden, hematological parameters, progression to leukemia, survival, pacritinib treatment patterns, patient demographic and clinical characteristics, and allogenic-hematopoietic stem cell transplant (allo-HSCT)-related outcomes. Data will be collected from medical charts of patients with pacritinib initiation between 01 June 2022 and 31 December 2025 with an end of study observation on 30 June 2026.

DROP-FPF is a clinical study that will assess whether an investigational medication called nerandomilast can reduce the risk of interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) getting worse over time. By learning more about people with early lung abnormalities, it may inform researchers how to reduce the risk of developing progressive pulmonary fibrosis.

This study aims to explore how painful and non-painful stimuli are processed in people with and without nerve pain with chronic SCI. We are recruiting individuals with spinal cord injury at T11 and above, with or without neuropathic pain in the leg, and who are able to stand with or without an assistive device. Study participation involves 3 in-person visits, each of which will last 2-3 hours. Compensation and mileage reimbursement are available for all study visits.